Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence

Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence

Ixabepilone demonstrates marked synergistic activity in combination with capecitabine, which served as the rationale for the evaluation of this combination in the clinic. Ixabepilone plus capecitabine is currently approved for patients with locally advanced or metastatic breast cancer (MBC) progress...

Full description

Bibliographic Details
Main Authors:	Francis Lee, Maria N. Jure-Kunkel, Mark E. Salvati
Format:	Article
Language:	English
Published:	SAGE Publishing 2011-01-01
Series:	Therapeutic Advances in Medical Oncology
Online Access:	https://doi.org/10.1177/1758834010386402

Similar Items

Profile and potential of ixabepilone in the treatment of pancreatic cancer
by: Smaglo BG, et al.
Published: (2014-07-01)

Combination of Ixabepilone and Capecitabine in Metastatic Triple Negative Breast Cancer. Clinical case
by: E. V. Glazkova, et al.
Published: (2019-12-01)

Ixabepilone: new perspectives for its use in breast cancer
by: A. A. Mescheryakov, et al.
Published: (2018-11-01)

Ixabepilone as Monotherapy or in Combination with Capecitabine for the Treatment of Advanced Breast Cancer
by: Katherine H. Rak Tkaczuk
Published: (2011-01-01)

Ixabepilone as Monotherapy or in Combination with Capecitabine for the Treatment of Advanced Breast Cancer
by: Katherine H. Rak Tkaczuk
Published: (2011-01-01)

Ixabepilone: Overview of Effectiveness, Safety, and Tolerability in Metastatic Breast Cancer
by: Nuhad K. Ibrahim
Published: (2021-07-01)

Advancements in the Treatment of Metastatic Breast Cancer (MBC): The Role of Ixabepilone
by: Massimo Cristofanilli
Published: (2012-01-01)

Management of advanced breast cancer with the epothilone B analog, ixabepilone
by: William Gradishar
Published: (2009-06-01)

Prediction of therapeutic response to paclitaxel, docetaxel and ixabepilone in breast cancer
by: Kadra, Gais
Published: (2011)

Fucoidan as a Marine Anticancer Agent in Preclinical Development
by: Jong-Young Kwak
Published: (2014-01-01)

Ixabepilone development across the breast cancer continuum: a paradigm shift
by: Nuhad K Ibrahim
Published: (2010-06-01)

Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer
by: Shannon Puhalla, et al.
Published: (2008-09-01)

Cancer during Pregnancy: A Review of Preclinical and Clinical Transplacental Transfer of Anticancer Agents
by: Laure Benoit, et al.
Published: (2021-03-01)

Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.
by: Ryoko Takahashi, et al.
Published: (2016-01-01)

The characterization of preclinical evidence for agents entering clinical development
by: Federico, Carole
Published: (2013)

Use of Yeast Chemigenomics and COXEN Informatics in Preclinical Evaluation of Anticancer Agents
by: Steven C. Smith, et al.
Published: (2011-01-01)

Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancer
by: Marta Vallee Cobham, et al.
Published: (2009-06-01)

Preclinical Pharmacology of BA-TPQ, a Novel Synthetic Iminoquinone Anticancer Agent
by: Ruiwen Zhang, et al.
Published: (2010-07-01)

Preclinical evaluation and identification of potent tubulin and Hsp27 inhibitors as anticancer agents
by: Lama, Rati
Published: (2015)

Preclinical and Clinical Evidence of Therapeutic Agents for Paclitaxel-Induced Peripheral Neuropathy
by: Takehiro Kawashiri, et al.
Published: (2021-08-01)

Cognitive deficits in schizophrenia and other neuropsychiatric disorders: Convergence of preclinical and clinical evidence
Published: (2015)

Exploring Polymeric Micelles for Improved Delivery of Anticancer Agents: Recent Developments in Preclinical Studies
by: Wei Fan, et al.
Published: (2013-03-01)

Use of vitamin C in anticancer therapy? – preclinical and clinical data overview
by: Katarzyna Regulska, et al.
Published: (2020-06-01)

A phase II trial of the epothilone B analog ixabepilone (BMS-247550) in patients with metastatic melanoma.
by: Patrick A Ott, et al.
Published: (2010-01-01)

Editorial on Cognitive deficits in schizophrenia and other neuropsychiatric disorders: Convergence of preclinical and clinical evidence
by: Ales eStuchlik, et al.
Published: (2014-12-01)

Synergistic Anticancer Effect of Tocotrienol Combined with Chemotherapeutic Agents or Dietary Components: A Review
by: Takahiro Eitsuka, et al.
Published: (2016-09-01)

Modified taxols as anticancer agents
by: Magri, Neal Francis
Published: (2015)

Quantitative polymerase chain reaction of gene expression in the preclinical and clinical development for anticancer drugs

Preclinical and Clinical Evidence of Antioxidant Effects of Antidepressant Agents: Implications for the Pathophysiology of Major Depressive Disorder
by: Guilherme A. Behr, et al.
Published: (2012-01-01)

Studies on the anticancer properties of pleurocidins: a preclinical evaluation
by: Hilchie, Ashley
Published: (2012)

New preclinical strategies for characterization and development of anticancer drugs
by: Karlsson, Henning
Published: (2017)

CpG plus radiotherapy: a review of preclinical works leading to clinical trial
by: Kathy A. Mason, et al.
Published: (2012-08-01)

Searching Synergistic Dose Combinations for Anticancer Drugs
by: Zuojing Yin, et al.
Published: (2018-05-01)

Sarecycline: A Review of Preclinical and Clinical Evidence
by: Moore AY, et al.
Published: (2020-08-01)

Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents
by: Daniel A. Ladin, et al.
Published: (2016-10-01)

Pharmacoeconomic characteristics of ixabepilone (Ixempra) monotherapy in patients with locally advanced and metastatic breast cancer resistant to treatment with anthracyclines, taxanes and capecitabin
by: A S Kolbin, et al.
Published: (2017-01-01)

Anticancer Potential of Citrus Juices and Their Extracts: A Systematic Review of Both Preclinical and Clinical Studies
by: Santa Cirmi, et al.
Published: (2017-06-01)

Preclinical Anticancer Activity of an Electron-Deficient Organoruthenium(II) Complex
by: Soldevila-Barreda, Joan J., et al.
Published: (2020)

Synergistic Interactions Between Anticancer Chemotherapeutics and Phenolic Compounds and Anticancer Synergy Between Polyphenols
by: Urszula Lewandowska, et al.
Published: (2014-01-01)

Cost-effectiveness analysis of ixabepilone use in monotherapy in patients with locally advanced and metastatic breast cancer resistant to treatment with anthracyclines, taxanes and capecitabin
by: A S Kolbin, et al.
Published: (2018-03-01)